Halaman 2 - Astrositoma Dokter Terbaik - TOP-60 dokter

Profesor Keil berspesialisasi dalam pencitraan canggih dan intervensi untuk astrositoma di Pusat Medis di Solingen.

• 16+ tahun dalam radiologi diagnostik dan intervensional
• Dilatih di bawah ahli radiologi ternama Profesor Christiane K. Kuhl
• Ahli dalam MRI, CT, dan intervensi yang dipandu ultrasonografi
• Kini menjabat sebagai Kepala Dokter Radiologi Diagnostik dan Intervensional

Prof. Elke Jaeger telah melakukan 1.100+ prosedur onkologi dan termasuk dalam jajaran ahli onkologi terbaik di Jerman selama 20 tahun terakhir.

• Kepala Onkologi dan Hematologi di Klinik Nordwest
• Spesialisasi dalam pengobatan sarkoma
• Profesor onkologi medis dan hemato-onkologi
• Anggota komisi ahli EORTC

Dr. Felix Bokstein memimpin Klinik Neuroonkologi di Ichilov – salah satu rumah sakit terbesar dan tercanggih di Israel, yang berfokus khusus pada tumor otak.

• Fokus utamanya adalah menangani tumor otak dan sumsum tulang belakang yang kompleks.
• Sebagai Kepala Klinik, ia mengawasi unit neuro-onkologi khusus.
• Pengalamannya mencakup penanganan glioma, astrositoma, dan keganasan SSP lainnya.
• Mengintegrasikan kemoterapi, terapi target, dan opsi uji klinis ke dalam rencana pengobatan.

Dr. Yildiz telah mempublikasikan banyak karya tentang tumor neuroendokrin dan kasus onkologi langka, dengan penelitian yang dimuat dalam jurnal medis internasional.

• Spesialisasi dalam tumor neuroendokrin dan presentasi kanker langka
• Mempublikasikan lebih dari 17 artikel peer-reviewed tentang topik onkologi
• Bekerja di Rumah Sakit Universitas Medipol Mega

Profesor Zvi Ram mengepalai European Association of Neurosurgical Societies (EANS) – sebuah peran tingkat tinggi yang menonjolkan kepemimpinannya di bidang ini.

• Berspesialisasi dalam bedah invasif minimal dan teknik pemetaan otak
• Menjadi ahli dalam operasi bedah saraf, termasuk stimulasi otak dalam (DBS)
• Melakukan bedah saraf dengan panduan gambar untuk tumor otak, menempuh pelatihan di Yunani dan Swiss
• Memimpin penelitian tentang terapi berbasis gen untuk kanker otak
• Menerima penghargaan Borenstein Award dari Brain & Behavior Research Foundation

Prof. Wolfgang Köstler berspesialisasi dalam terapi kanker terarget, dengan fokus pada keganasan payudara dan ginekologi di Wiener Privatklinik.

• Pengalaman lebih dari 20 tahun dalam onkologi medis
• Pakar dalam pengembangan biomarker dan biologi tumor
• Associate Professor di Medical University of Vienna
• Wakil Kepala Divisi Klinis Onkologi

Associate Professor Tahsin Ozatli berspesialisasi dalam kanker payudara, paru-paru, dan gastrointestinal di Rumah Sakit Universitas Istinye Liv.

• Spesialis Penyakit Dalam dengan pengalaman onkologi yang luas
• Berpraktik di Klinik Onkologi Ankara dan Rumah Sakit Pelatihan Regional Erzurum
• Lulusan Fakultas Kedokteran Universitas Selcuk
• Dipromosikan menjadi Associate Professor pada tahun 2016

Spesialis dalam astrositoma dan menempuh pendidikan di institusi medis ternama di Turki – Dr. Alemdar menghadirkan perawatan onkologi berbasis bukti ke Kompleks Rumah Sakit Medical Park Antalya.

• Menyelesaikan pelatihan onkologi medis di Universitas Akdeniz
• Lebih dari 14 tahun merawat kanker di lingkungan rumah sakit dan universitas
• Pengalaman luas di rumah sakit pendidikan dan penelitian
• Bekerja sama dengan tim multidisiplin untuk pengobatan komprehensif

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Assoc. Prof. Nail Paksoy membawa keahlian luas dalam onkologi medis, dengan spesialisasi dalam perawatan astrositoma di Universitas Medipol Istanbul.

• Tersertifikasi Dewan ESMO dalam Onkologi Medis
• Peserta aktif dalam uji klinis internasional untuk perawatan kanker
• Menerbitkan berbagai artikel penelitian tentang terapi onkologi inovatif

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Prof. Zvi Cohen is Director of the Neurosurgery Department and the Neuro-Oncology Unit at Sheba Medical Center. He is a neurosurgeon and neuro-oncology expert. He was included in Forbes Israel’s Best Doctors 2025. He leads clinical research on drug therapies for malignant brain tumors. He also founded Sheba’s brain tumor tissue bank.

He is board-certified in neurosurgery. He trained at Tel Aviv University. He completed fellowships in neuroradiology at Beth Israel and in neurosurgical oncology at MD Anderson. His practice covers complex brain, pituitary, spine, and spinal cord tumors. He has expertise in stereotactic biopsies, image-guided resections, intraoperative MRI, navigation systems, and radiosurgery. He is a member of the Society for Neuro-Oncology and the Israeli Association of Neurological Surgeons.

Menetapkan kriteria ketat pertama untuk mendiagnosis sindrom neurologis paraneoplastik – sebuah kemajuan kunci dalam neuro-onkologi. Dr. Graus adalah peneliti emeritus di IDIBAPS.

• Mantan kepala neurologi di Hospital Clinic, Barcelona
• Pendiri dan mantan presiden European Association of Neuro-Oncology
• PhD dari Universitat Autònoma de Barcelona
• Spesialisasi dalam glioma dan limfoma otak primer

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Maha Yahia is a medical oncologist and hemato-oncologist. She provides assessment, diagnosis, and treatment planning. Her treatments include chemotherapy, targeted therapy, and immunotherapy. She cares for patients with breast, genitourinary, gynecologic, thoracic, gastrointestinal, and rare cancers.

Education: M.B.B.Ch, Kasr El-Aini, Cairo University (1997–2003). Master in Hemato-oncology, National Cancer Institute, Cairo University (2008). Doctoral Degree in Hemato-oncology, National Cancer Institute, Cairo University (2015).

Experience: Resident in Medical Oncology, Maadi AFMC (2005–2010). Visitor Resident, NCI Cairo (2008–2009). Consultant Assistant, Prof. Hussein Khaled Clinic (2010–2017). Specialist, International Medical Center (2011–2012), Wadi El Nile Hospital (2013–2014), and Maadi AFMC (2011–2018). Head, Clinical Research Support Team, Maadi AFMC (2016–2018). Major (2014–2016) and Lt. Colonel Doctor (2016–2018), Egyptian Armed Forces. Lecturer of Clinical Research, AFCM (2019–2021).

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.